

Ali Latif

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9712413/publications.pdf>

Version: 2024-02-01

31
papers

2,715
citations

331670

21
h-index

477307

29
g-index

51
all docs

51
docs citations

51
times ranked

2623
citing authors

#	ARTICLE	IF	CITATIONS
1	Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, e1188-e1191.	5.8	38
2	Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. <i>Nature Communications</i> , 2022, 13, 532.	12.8	53
3	Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2. <i>PLoS ONE</i> , 2022, 17, e0262897.	2.5	1
4	Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar. <i>JAMA Internal Medicine</i> , 2022, 182, 197.	5.1	81
5	Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar's experience. <i>Journal of Global Health</i> , 2022, 12, 05004.	2.7	7
6	Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, e361-e367.	5.8	83
7	Reporting of RT-PCR cycle threshold (Ct) values during the first wave of COVID-19 in Qatar improved result interpretation in clinical and public health settings. <i>Journal of Medical Microbiology</i> , 2022, 71, .	1.8	7
8	Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections. <i>Journal of Travel Medicine</i> , 2022, 29, .	3.0	37
9	Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. <i>Nature Communications</i> , 2022, 13, .	12.8	188
10	Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease. <i>Vaccines</i> , 2022, 10, 1036.	4.4	2
11	Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting. <i>Clinical Infectious Diseases</i> , 2021, 73, e1830-e1840.	5.8	154
12	Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. <i>Journal of Global Health</i> , 2021, 11, 05005.	2.7	71
13	Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months. <i>Infection, Genetics and Evolution</i> , 2021, 88, 104684.	2.3	22
14	Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. <i>Scientific Reports</i> , 2021, 11, 6233.	3.3	117
15	Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. <i>BMJ Innovations</i> , 2021, 7, 327-336.	1.7	27
16	SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab221.	0.9	58
17	Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. <i>Emerging Infectious Diseases</i> , 2021, 27, 1343-1352.	4.3	74
18	Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. <i>Journal of Travel Medicine</i> , 2021, 28, .	3.0	69

#	ARTICLE	IF	CITATIONS
19	SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. <i>EClinicalMedicine</i> , 2021, 35, 100861.	7.1	153
20	SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. <i>IScience</i> , 2021, 24, 102646.	4.1	79
21	Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population. <i>Scientific Reports</i> , 2021, 11, 11837.	3.3	14
22	mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. <i>Nature Medicine</i> , 2021, 27, 1614-1621.	30.7	337
23	SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar. <i>Scientific Reports</i> , 2021, 11, 18182.	3.3	49
24	Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination. <i>International Journal of Infectious Diseases</i> , 2021, 110, 353-358.	3.3	74
25	SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	49
26	Risk factors for breakthrough SARS-CoV-2 infection in vaccinated healthcare workers. <i>PLoS ONE</i> , 2021, 16, e0258820.	2.5	37
27	Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1930.	7.4	140
28	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. <i>Nature Medicine</i> , 2021, 27, 2136-2143.	30.7	346
29	Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003879.	8.4	54
30	Title is missing!. <i>Qatar Medical Journal</i> , 2001, 2001, .	0.5	1
31	COVID-19 disease severity in persons infected with the Omicron variant compared with the Delta variant in Qatar. <i>Journal of Global Health</i> , 0, 12, .	2.7	48